Publication Information
Available Issues

JAIDS: Journal of Acquired Immune Deficiency Syndromes


Featured in This Issue:
T-Cell Activation Predict Antiretroviral Success in Salvage Therapy of HIV ... Bacterial Vaginosis and Vaginal Yeast, Not Vaginal Cleansing, HIV...


Available Content
2008
DOTS
T-Cell Activation Predict Antiretroviral Success in Salvage Therapy of HIV ... Bacterial Vaginosis and Vaginal Yeast, Not Vaginal Cleansing, HIV...
DOTS

Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic ... Long-term Subcutaneous Tissue Changes Among Antiretroviral-Naive Persons...
DOTS

ART Drug Resistance and Risk Behavior Among Recently HIV-infectected... Clinical Outcome of HIV-infected Antiretroviral-naive Patients ...
DOTS

Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir... Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV...
DOTS

Effects of Depression on Adherence to Highly Active Antiretroviral Therapy ... Survival and Serious Cardiovascular Events in HIV-infected Patients, ART...
DOTS

A Volume-outcome Study of Hospital Patients With HIV Disease... HIV Progression and Assessment of the Optimal Time to Initiate ART...
DOTS

Racial Disparities in HIV: Lessons From Sexually Transmitted Infections ... Mental Health and Substance Abuse Factors on HIV Prevention and Treatment... Tenofovir/Emtricitabine/Efavirenz vs. Zidovudine/Lamivudine + Efavirenz... Initiation of Antiretroviral Therapy at CD4 Cell Counts...
DOTS

2007
DOTS
Randomized Study of Poly-L-Lactic Acid for HIV Facial Lipoatrophy... Directly Administered Antiretroviral Therapy (DAART)...
DOTS

Routine HIV Screening in the Emergency Department... IRIS: Risk Factors and Treatment Implications...
DOTS

FRAM Study: Upper Trunk and Visceral Adipose Tissue in HIV... Magnetic Resonance Spectroscopy of Hepatic Lipid Content...
DOTS

Integrase Inhibitor Raltegravir Has Rapid and Durable Antiretroviral Effect... How Homosexual Men Believe They Became Infected With HIV...
DOTS

Adults With CD4 >500 on HAART -- Same Mortality Rates as General Population... Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir...
DOTS

Comparing Initial HAART Response in US and Brazil... Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants...
DOTS

The Relation Between Symptoms, Viral Load (VL), and Viral Set Point... 80-Week Data From a Phase 2 Study...
DOTS

A Microchip Approach for Practical Label-Free CD4+ T-Cell Counting... Recombinant Human Growth Hormone to Treat HARS...
DOTS

CD4 Cell Counts of 800 Cells/mm3 Feasable After 7 Years of HAART... Editorial: When To Initiate HIV ART Therapy...
DOTS

Prospective Screening for HLA-B*5701 Avoids Abacavir Hypersensitivity... The Relationship Between Methamphetamine and Popper Use...
DOTS

Long-Term Body Composition and Metabolic Changes in ART Naive Persons... Metabolic Effects of Protease Inhibitor-Sparing ART Regimens Given for HIV...
DOTS

Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir... Two and a Half Years of Routine HIV Testing in Botswana...
DOTS

Pretreatment Factors With 3-Year Virologic and Immunologic Responses to ART... Occult Hepatitis B Virus in a Prospective Cohort of HIV-Infected Patients...
DOTS

Predictive Value of Early Virologic Response in HIV/Hepatitis C Coinfection... Effects of a Behavioral Intervention to Reduce Risk of HIV Transmission...
DOTS

Characteristics of Persons With Recently Acquired HIV Infection... Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic...
DOTS

2006
DOTS
Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518... Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz ...
DOTS

Hazardous Alcohol Use: A Risk Factor for Non-Adherence in HIV Infection... 1-Year Outcomes of Infective Endocarditis in an Urban HIV Cohort...
DOTS

Measuring the Outcomes of a Comprehensive HIV Care Course... Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate...
DOTS

Occurrence of Vaginal Infections Among HIV-Infected and High-Risk Women... Disadvantages of Structured Treatment With Multidrug-Resistant HIV...
DOTS

Antiviral Activity, Pharmacokinetics, and Dose Response of GS-9137... Mortality in the Highly Active Antiretroviral Therapy Era...
DOTS

Micronutrient Supplementation Increases CD4 Count in HIV-Infected People... Fat Distribution in Women With HIV Infection...
DOTS

Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery ... Antiretrovirals Induce Direct Endothelial Dysfunction in Vivo...
DOTS

Osteonecrosis in Patients Infected With HIV... Highly Active Antiretroviral Therapy...
DOTS

Evaluating T-cell Count After Treatment Interruption... Nucleoside Activity and HIV Prevention in Infants...
DOTS

Drug Resistance & Efficacy of First-Line Antiretroviral Therapy...
DOTS

Pharmacologic Optimization of Protease Inhibitors and POPIN... Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1...
DOTS

Nonadherence to Antiretroviral Therapy in HIV-Infected Patients...
DOTS

Bioequivalence of Nevirapine, Zidovudine, and Lamivudine... Diagnosis of Hepatic Fibrosis and Cirrhosis ...
DOTS

Acute Hepatitis C Infection in HIV-Infected Patients... Reducing Unprotected Sexual Behavior Among HIV-Infected Patients...
DOTS

2005
DOTS
Prednisolone Pharmacokinetics... Infection Does Not Affect the Performance of Noninvasive Markers...
DOTS

Safety of Enfuvirtide in Combination With Antiretrovirals... Efficacy of Enfuvirtide in Treatment-Experienced HIV-1 Patients...
DOTS

Discordant Immunologic and Virologic Responses to Therapy... Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance...
DOTS

Herpes Zoster Among HIV Patients in Antiretroviral Therapy Era...
DOTS

Protease Inhibitor Use in 233 Pregnancies... HIV-1 Drug Resistance Among Patients on Potent Combo of ART...
DOTS

Race, Sociodemographics, Behavior - HAART in Women... HAART Retreatment in CD4-Guided Therapy vs. Continous HAART...
DOTS

... Cervical Intraepithelial Neoplasia - Women With HIV...
DOTS

Results of AIDS Clinical Trials Group 5108 Study... Induction With Abacavir/Lamivudine/Zidovudine Plus Efavirenz ...
DOTS

Incidence of Pancreatitis in HIV-1-Infected Individuals Enrolled... Intermittent Low-Level Viremia in Very Early Primary HIV-1...
DOTS

Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic... Increased Dose of Lopinavir/Ritonavir Compensates for...
DOTS

Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approach... Use of the Serologic Testing Algorithm for Recent HIV...
DOTS

... Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine...
DOTS

Persistence of Nevirapine Exposure During the Postpartum Period ...
DOTS

... Outcomes of Offering Rapid Point-of-Care HIV Testing in A ...
DOTS

Risk Factors for In Utero and Intrapartum Transmission of HIV... Diabetes, Insulin Resistance, and Dementia Among HIV-1-Infected ...
DOTS

2004
DOTS
Selection of Antiretroviral Therapy Guided by Genotypic or... HIV-Associated Anal Cancer: Has Highly Active Antiretroviral...
DOTS

Renal Dysfunction With Tenofovir-Containing Highly Active... Case-Control Study of Diabetes Mellitus in HIV-Infected Patients...
DOTS

Patterns of Resistance Emerging in HIV-1 From...
DOTS

... Progressive Multifocal Leukencephalopathy in Patients on Highly ...
DOTS

... Effect of Persistent Moderate Viremia on Disease Progression Dur...
DOTS

Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of... Comparison of Once-Daily Atazanavir With Efavirenz, Each in... Comparison of Once-Daily Atazanavir With Efavirenz, Each in ... HIV Transmission Risk Behavior Among Men and Women Living With...
DOTS

Perspectives on Adherence and Simplicity for HIV-Infected... Maternal Toxicity With Continuous Nevirapine in Pregnancy:...
DOTS

Changes in Total Lymphocyte Count as a Surrogate for Changes in ... Highly Active Antiretroviral Therapy Improves Neurocognitive ...
DOTS

Efavirenz Versus Nevirapine in Current Clinical Practice... Herpes Simplex Virus-2 and HIV-1 Acquisition/Transmission...
DOTS

Correlates of National HIV Seroprevalence: An Ecologic Analysis... Comparison of Drug Resistance Mutations...
DOTS

Impact of Adherence on CD4 Cell Count Among HIV-Infected... Renal Tubular Dysfunction Associated With Tenofovir Therapy...
DOTS

Transport of HIV Protease Inhibitors Through the Blood-Brain... Comparative Therapy for HIV-Positive Patients With Candidiasis... Nevirapine Resistance Mutations in Women...
DOTS

The NEAT Study... Differences in HIV Disease Progression by Injecting Drug Use...
DOTS

2003
DOTS
Selective Neuronal Damage in Methamphetamine-User AIDS Patients... HIV-1 Antiretroviral-Treated Patients With Viral Suppression...
DOTS

Once-Weekly Epoetin Alfa Dosing in Anemix HIV Patients... Grade 4 Events as Important as AIDS Events in the Era of HAART...
DOTS

Low Rate of Mother-to-Child Transmission of HIV-1... Perinatal HIV Prevention: What Do We Really Know?...
DOTS

Changes in HIV-Related Preventive Behavior in the US Population... Pharmacokinetics of Indinavir/Ritonavir...
DOTS

Mitochondrial Dysfunction in HIV-Infected People... Modeling the Time Course of CD4 T-Lymphocyte Counts...
DOTS

An Objective Lipodystrophy Severity Grading Scale... Lopinavir Plasma Concentrations and Changes in Lipid Levels Duri...
DOTS

HIV-1 Infection and Maturation of Myeloid Dendritic Cells... Coronary Heart Disease in HIV-Infected Individuals...
DOTS

The Impact of Hepatitis C Virus Coinfection on HIV Progression... Urban HIV-1 Clinics in the Era of Active Antiretroviral Therapy ...
DOTS

Pretreatment of Chronic Active Hepatitis C... Incomplete CD4 T Cell Recovery in HIV-1 Infection...
DOTS

Extended Treatment With Tenofovir Disoproxil Fumarate... Rapid Communication: HIV-1 Protease and Reverse Transcriptase ...
DOTS

Comparison of Two Strategies for Administering Nevirapine in HIV... Toxicity and the Concurrent Use of Lopinavir/Ritonavir...
DOTS

Pharmacokinetics of Once-Daily Saquinavir ... Antiretroviral Therapy and Persistence of HIV RNA in Semen ... Severe Hepatotoxicity with Combination Antiretroviral Treatment... Protease Inhibitor-Associated Diabetes Mellitus...
DOTS

Lopinavir in Individuals Experiencing Protease Inhibitor Failure... Once-Daily Saquinavir-sgc Plus Low-Dose Ritonavir ...
DOTS

One Year of Highly Active Antiretroviral Therapy ... Results of a Phase Two Clinical Trial at 48 Weeks...
DOTS

Back to Top


Related Resources
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.